EANM-SNMMI联合指南:2-[18F]FDG PET/CT在非特殊型乳腺癌中的作用(获ACR、ESSO、ESTRO、EUSOBI/ESR及EUSOMA认可)
该指南由EANM与SNMMI牵头、多学科协会参与制定,通过文献复习与专家讨论,按NICE标准对2-[18F]FDG PET/CT在非特殊型乳腺癌中的适应证进行推荐。指南指出定量PET特征(SUV、MTV、TLG)是有价值的预后参数,基线分期中该检查从IIB期至IV期发挥作用,并可用于疗效评估与复发检测。
要点
- 定量PET特征(SUV、MTV、TLG)是有价值的预后参数。
- 基线分期中,2-[18F]FDG PET/CT从IIB期至IV期发挥作用。
- 评估疗效时应在认证扫描仪上按PERCIST、EORTC PET或EANM免疫治疗反应标准报告。
核心结论
- 2-[18F]FDG PET/CT在乳腺癌管理中极为有用,多项临床场景下与其他影像模态相比其效用有广泛证据支持。
研究设计与样本
- 由EANM和SNMMI两个核医学学会的专家牵头,并有ACR、ESSO、ESTRO、EUSOBI/ESR和EUSOMA等重要学会代表参与,通过文献复习和专家讨论制定国际多学科指南。
- 推荐意见按美国国家卫生与临床优化研究所(NICE)标准进行评分。
主要发现
- 定量PET特征(SUV、MTV、TLG)是有价值的预后参数。
- 基线分期中,2-[18F]FDG PET/CT从IIB期至IV期发挥作用。
- 评估治疗反应时,2-[18F]FDG PET/CT应在认证扫描仪上进行,并视情况按PERCIST、EORTC PET或EANM免疫治疗反应标准报告。
- 2-[18F]FDG PET/CT可能有助于评估早期代谢反应,特别是在非转移性三阴性和HER2+肿瘤中。
- 当常规影像方法结果不明确且存在临床和/或实验室复发怀疑时,2-[18F]FDG PET/CT有助于检测复发部位和范围。
关键数值与推荐
- 推荐意见按NICE标准评分。
- 基线分期中,2-[18F]FDG PET/CT从IIB期至IV期发挥作用。
- 评估疗效时应在认证扫描仪上按PERCIST、EORTC PET或EANM免疫治疗反应标准报告。
- 2-[18F]FDG PET/CT可能有助于评估早期代谢反应,特别是在非转移性三阴性和HER2+肿瘤中。
- 当常规影像方法结果不明确且存在临床和/或实验室复发怀疑时,2-[18F]FDG PET/CT有助于检测复发部位和范围。
临床怎么用
- 基线分期中,2-[18F]FDG PET/CT从IIB期至IV期发挥作用。
- 评估治疗反应时,2-[18F]FDG PET/CT应在认证扫描仪上进行,并视情况按PERCIST、EORTC PET或EANM免疫治疗反应标准报告。
- 2-[18F]FDG PET/CT可能有助于评估早期代谢反应,特别是在非转移性三阴性和HER2+肿瘤中。
- 当常规影像方法结果不明确且存在临床和/或实验室复发怀疑时,2-[18F]FDG PET/CT有助于检测复发部位和范围。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There is much literature about the role of 2-[18F]FDG PET/CT in patients with breast cancer (BC). However, there exists no international guideline with involvement of the nuclear medicine societies about this subject. PURPOSE: To provide an organized, international, state-of-the-art, and multidisciplinary guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and representation of important societies in the field of BC (ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). METHODS: Literature review and expert discussion were performed with the aim of collecting updated information regarding the role of 2-[18F]FDG PET/CT in patients with no special type (NST) BC and summarizing its indications according to scientific evidence. Recommendations were scored according to the National Institute for Health and Care Excellence (NICE) criteria. RESULTS: Quantitative PET features (SUV, MTV, TLG) are valuable prognostic parameters. In baseline staging, 2-[18F]FDG PET/CT plays a role from stage IIB through stage IV. When assessing response to therapy, 2-[18F]FDG PET/CT should be performed on certified scanners, and reported either according to PERCIST, EORTC PET, or EANM immunotherapy response criteria, as appropriate. 2-[18F]FDG PET/CT may be useful to assess early metabolic response, particularly in non-metastatic triple-negative and HER2+ tumours. 2-[18F]FDG PET/CT is useful to detect the site and extent of recurrence when conventional imaging methods are equivocal and when there is clinical and/or laboratorial suspicion of relapse. Recent developments are promising. CONCLUSION: 2-[18F]FDG PET/CT is extremely useful in BC management, as supported by extensive evidence of its utility compared to other imaging modalities in several clinical scenarios.
引用
- Vaz SC, Woll JPP, Cardoso F, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA). Eur J Nucl Med Mol Imaging. 2024. PMID: 38740576. doi:10.1007/s00259-024-06696-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。